124 related articles for article (PubMed ID: 25323306)
1. Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells.
Dong Z; Ren L; Lin L; Li J; Huang Y; Li J
Mol Med Rep; 2015 Jan; 11(1):682-90. PubMed ID: 25323306
[TBL] [Abstract][Full Text] [Related]
2. Reversing effect and mechanism of soluble resistance-related calcium-binding protein on multidrug resistance in human lung cancer A549/DDP cells.
Gao Y; Li W; Liu X; Gao F; Zhao X
Mol Med Rep; 2015 Mar; 11(3):2118-24. PubMed ID: 25394367
[TBL] [Abstract][Full Text] [Related]
3. [The effect and mechanism of microRNA-21 on cis-dichlorodiamineplatinum resistance in lung cancer cell strain].
Ren L; Huang C; Liu YH; Yu Y; Lin L; Wen LJ
Zhonghua Yi Xue Za Zhi; 2016 May; 96(18):1454-8. PubMed ID: 27266356
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-β/Smad2/STAT3/STAT5 pathway.
Sun W; Ma Y; Chen P; Wang D
Mol Med Rep; 2015 May; 11(5):3854-9. PubMed ID: 25586740
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.
Ma Y; Li X; Cheng S; Wei W; Li Y
Mol Med Rep; 2015 Jan; 11(1):625-32. PubMed ID: 25339370
[TBL] [Abstract][Full Text] [Related]
6. Effect and mechanism of peroxisome proliferator-activated receptor-γ on the drug resistance of the U-87 MG/CDDP human malignant glioma cell line.
Han S; Lv X; Wang Y; Gong H; Zhang C; Tong A; Zhang B; Yao H
Mol Med Rep; 2015 Aug; 12(2):2239-46. PubMed ID: 25891367
[TBL] [Abstract][Full Text] [Related]
7. miR-181a and miR-630 regulate cisplatin-induced cancer cell death.
Galluzzi L; Morselli E; Vitale I; Kepp O; Senovilla L; Criollo A; Servant N; Paccard C; Hupé P; Robert T; Ripoche H; Lazar V; Harel-Bellan A; Dessen P; Barillot E; Kroemer G
Cancer Res; 2010 Mar; 70(5):1793-803. PubMed ID: 20145152
[TBL] [Abstract][Full Text] [Related]
8. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells.
Chen Z; Ma T; Huang C; Zhang L; Lv X; Xu T; Hu T; Li J
Cell Signal; 2013 Dec; 25(12):2693-701. PubMed ID: 24018051
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Qin X; Yu S; Zhou L; Shi M; Hu Y; Xu X; Shen B; Liu S; Yan D; Feng J
Int J Nanomedicine; 2017; 12():3721-3733. PubMed ID: 28553110
[TBL] [Abstract][Full Text] [Related]
10. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2.
Qiu T; Zhou L; Wang T; Xu J; Wang J; Chen W; Zhou X; Huang Z; Zhu W; Shu Y; Liu P
Int J Mol Med; 2013 Sep; 32(3):593-8. PubMed ID: 23856992
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
[TBL] [Abstract][Full Text] [Related]
12. MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression.
Zang YS; Zhong YF; Fang Z; Li B; An J
Cancer Gene Ther; 2012 Nov; 19(11):773-8. PubMed ID: 22996741
[TBL] [Abstract][Full Text] [Related]
13. miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.
Bar J; Gorn-Hondermann I; Moretto P; Perkins TJ; Niknejad N; Stewart DJ; Goss GD; Dimitroulakos J
Clin Lung Cancer; 2015 Nov; 16(6):e121-9. PubMed ID: 25703099
[TBL] [Abstract][Full Text] [Related]
14. Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line.
Zhang K; Wang X; Wang H
Mol Med Rep; 2014 Oct; 10(4):2065-72. PubMed ID: 25109654
[TBL] [Abstract][Full Text] [Related]
15. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
Zhu W; Xu H; Zhu D; Zhi H; Wang T; Wang J; Jiang B; Shu Y; Liu P
Cancer Chemother Pharmacol; 2012 Mar; 69(3):723-31. PubMed ID: 21993663
[TBL] [Abstract][Full Text] [Related]
16. DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21
Xu S; Huang H; Chen YN; Deng YT; Zhang B; Xiong XD; Yuan Y; Zhu Y; Huang H; Xie L; Liu X
Cell Cycle; 2016 Nov; 15(21):2920-2930. PubMed ID: 27559850
[TBL] [Abstract][Full Text] [Related]
17. MiR-1 targets PIK3CA and inhibits tumorigenic properties of A549 cells.
Yu QQ; Wu H; Huang X; Shen H; Shu YQ; Zhang B; Xiang CC; Yu SM; Guo RH; Chen L
Biomed Pharmacother; 2014 Mar; 68(2):155-61. PubMed ID: 24486107
[TBL] [Abstract][Full Text] [Related]
18. Reversal of multidrug resistance in gastric cancer cells by E2F-1 downregulation in vitro and in vivo.
Yan LH; Wang XT; Yang J; Kong FB; Lian C; Wei WY; Luo W; Xie YB; Xiao Q
J Cell Biochem; 2014 Jan; 115(1):34-41. PubMed ID: 24038122
[TBL] [Abstract][Full Text] [Related]
19. Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP).
Wang Q; Zhong M; Liu W; Li J; Huang J; Zheng L
Exp Lung Res; 2011 Sep; 37(7):427-34. PubMed ID: 21787234
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis.
Guo L; Liu Y; Bai Y; Sun Y; Xiao F; Guo Y
Eur J Cancer; 2010 Jun; 46(9):1692-702. PubMed ID: 20371173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
